Skip to content

Side by side

CJC-1295 vs Hexarelin

Both are discussed for muscle & performance and anti-aging & longevity. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.

CJC-1295 and Hexarelin compared on what BioAlmanac records.
 CJC-1295Hexarelin
What it isA GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.The most potent growth hormone releasing peptide of the three, and the only one that reliably stops working. Its response fades within about two weeks of continuous use.
EvidenceHow much human evidence exists, not how well it works.Early human trialsEarly human trials
Regulatory statusReviewed 2026-08-12Not approved for human use in the United States. The FDA has identified CJC-1295 as a substance raising concerns for use in compounded preparations. Sold only as a research chemical.Not approved for human use in any jurisdiction. Reached early-phase clinical study in the 1990s; development did not continue, in part because the growth hormone response was not sustained. Sold only as a research chemical.
RoutesSubcutaneousSubcutaneous
Half-life0.5 hours0.9 hours
Cheapest per mgVials only, read from vendors' own listings and dated on the price index.$2.40/mg$5.91/mg
Median per mg$7.25/mg$8.82/mg
Vendors with a price4017
Storage once mixedRefrigerated at 2–8 °C. Do not freeze once mixed.Refrigerated at 2–8 °C. Do not freeze once mixed.

Compare two other compounds · The full price index

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.